Antibody Drug Conjugates Market is expected to generate $3.2 Billion by the end of 2025.
CHAPTER 1. INTRODUCTION 1.1. RESEARCH METHODOLOGY 1.1.1. ERC desk research 1.1.2. ERC data synthesis 1.1.3. Data validation and market feedback 1.1.4. ERC data sources CHAPTER 2. ANTIBODY DRUG CONJUGATES MARKET OVERVIEW 2.1. ANTIBODY DRUG CONJUGATES MARKET INTRODUCTION 2.2. GLOBAL ANTIBODY DRUG CONJUGATES MARKET REVENUE AND GROWTH RATE, 2017-2025 2.2.1. Global Antibody Drug Conjugates Market Revenue (Million USD) and Growth Rate (%), (2017-2025) CHAPTER 3. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY DRUG, 2017-2025 3.1. ADCETRIS 3.2. KADCYLA 3.3. GLOBAL ANTIBODY DRUG CONJUGATES MARKET REVENUE BY DRUG, 2017-2025 3.3.1. Global Antibody Drug Conjugates Market Revenue (Million USD) and Share (%) By Drug, 2017-2025 3.3.2. Adcetris Market Revenue and Growth Rate, 2017-2025 3.3.3. Kadcyla Market Revenue and Growth Rate, 2017-2025 Note: Similar information coverage has been provided for by mechanism of action segment. CHAPTER 4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY APPLICATION, 2017-2025 4.1. LYMPHOMA 4.2. BREAST CANCER 4.3. OTHERS 4.4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET REVENUE BY APPLICATION, 2017-2025 4.4.1. Global Antibody Drug Conjugates Market Revenue (Million USD) and Share (%) By Application, 2017-2025 4.4.2. Lymphoma Market Revenue and Growth Rate, 2017-2025 4.4.3. Breast cancer Market Revenue and Growth Rate, 2017-2025 4.4.4. Others Market Revenue and Growth Rate, 2017-2025 CHAPTER 5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY REGION, 2017-2025 5.1. NORTH AMERICA 5.1.1. U.S. 5.1.2. Canada 5.1.3. Mexico 5.2. EUROPE 5.2.1. U.K. 5.2.2. France 5.2.3. Germany 5.2.4. Italy 5.2.5. Spain 5.2.6. Rest of Europe 5.3. ASIA PACIFIC 5.3.1. China 5.3.2. Japan 5.3.3. India 5.3.4. Korea 5.3.5. Rest of APAC 5.4. SOUTH AMERICA 5.4.1. Brazil 5.4.2. Rest of South America 5.5. REST OF THE WORLD 5.5.1. Middle East 5.5.2. Africa 5.6. GLOBAL ANTIBODY DRUG CONJUGATES MARKET REVENUE BY REGION, 2017-2025 5.6.1. Global Antibody Drug Conjugates Market Revenue (Million USD) and Share (%) By Region, 2017-2025 5.6.2. North America Market Revenue and Growth Rate, 2017-2025 5.6.3. Europe Market Revenue and Growth Rate, 2017-2025 5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025 5.6.5. South America Market Revenue and Growth Rate, 2017-2025 5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025 CHAPTER 6. MARKET DETERMINANTS 6.1. MARKET DRIVERS 6.2. MARKET RESTRAINTS 6.3. MARKET OPPORTUNITIES 6.4. MARKET DETERMINANTS RADAR CHART CHAPTER 7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET COMPETITION BY SERVICE PROVIDERS 7.1. GLOBAL ANTIBODY DRUG CONJUGATES REVENUE AND SHARE BY SERVICE PROVIDERS (2017-2025) 7.1.1. Global Antibody Drug Conjugates Revenue (Million USD) and Share (%) by Service Providers (2017-2025) 7.2. ANTIBODY DRUG CONJUGATES MARKET COMPETITIVE SITUATION AND TRENDS 7.2.1. Antibody Drug Conjugates Market Share (%) of Top 3 Service Providers 7.2.2. Antibody Drug Conjugates Market Share (%) of Top 5 Service Providers CHAPTER 8. COMPANY PROFILES 8.1. SEATTLE GENETICS INC. 8.1.1. Business Overview 8.1.2. Company Basic Information 8.1.3. Antibody Drug Conjugates Product Details 8.1.4. Seattle Genetics Inc. Antibody Drug Conjugates Revenue and Gross Margin 8.2. ROCHE HOLDING AG 8.2.1. Business Overview 8.2.2. Company Basic Information 8.2.3. Antibody Drug Conjugates Product Details 8.2.4. Roche Holding AG Antibody Drug Conjugates Revenue and Gross Margin 8.3. IMMUNOGEN, INC. 8.3.1. Business Overview 8.3.2. Company Basic Information 8.3.3. Antibody Drug Conjugates Product Details 8.3.4. ImmunoGen, Inc. Antibody Drug Conjugates Revenue and Gross Margin 8.4. GENENTECH INC. 8.4.1. Business Overview 8.4.2. Company Basic Information 8.4.3. Antibody Drug Conjugates Product Details 8.4.4. Genentech Inc. Antibody Drug Conjugates Revenue and Gross Margin 8.5. AGENSYS, INC. 8.5.1. Business Overview 8.5.2. Company Basic Information 8.5.3. Antibody Drug Conjugates Product Details 8.5.4. Agensys, Inc. Antibody Drug Conjugates Revenue and Gross Margin 8.6. BAYER HEALTHCARE PHARMACEUTICALS 8.6.1. Business Overview 8.6.2. Company Basic Information 8.6.3. Antibody Drug Conjugates Product Details 8.6.4. Bayer Healthcare Pharmaceuticals Antibody Drug Conjugates Revenue and Gross Margin 8.7. VACCINEX INC. 8.7.1. Business Overview 8.7.2. Company Basic Information 8.7.3. Antibody Drug Conjugates Product Details 8.7.4. Vaccinex Inc. Antibody Drug Conjugates Revenue and Gross Margin 8.8. CONCORTIS BIOTHERAPEUTICS 8.8.1. Business Overview 8.8.2. Company Basic Information 8.8.3. Antibody Drug Conjugates Product Details 8.8.4. Concortis Biotherapeutics Antibody Drug Conjugates Revenue and Gross Margin 8.9. CELLDEX THERAPEUTICS INC. 8.9.1. Business Overview 8.9.2. Company Basic Information 8.9.3. Antibody Drug Conjugates Product Details 8.9.4. Celldex Therapeutics Inc. Antibody Drug Conjugates Revenue and Gross Margin 8.10. DAIICHI SANKYO 8.10.1. Business Overview 8.10.2. Company Basic Information 8.10.3. Antibody Drug Conjugates Product Details 8.10.4. Daiichi Sankyo Antibody Drug Conjugates Revenue and Gross Margin CHAPTER 9. ANTIBODY DRUG CONJUGATES MARKET VALUE CHAIN ANALYSIS 9.1. ANTIBODY DRUG CONJUGATES INDUSTRIAL CHAIN ANALYSIS 9.2. CONSUMER ANALYSIS 9.2.1. Consumer 1 9.2.2. Consumer 2 9.2.3. Consumer 3 9.2.4. Consumer 4